LIMNW Liminatus Pharma, Inc. - Warrants
$0.06
Price · Aug 19, 2026
Fundamentals as of Aug 14, 2026
52W Range
$0–$0
36% of range
Analyst Rating
—
Price Target
—
P/E (TTM)
—
ROE
109.6%
Net Profit Margin
—
LIMNW Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.06
Market Cap
—
P/E (TTM)
—
EPS (TTM)
$-0.43
Revenue (TTM)
—
Div Yield
—
ROE
109.6%
Debt/Equity
-0.1
52W Range
$0 – $0
LIMNW Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
$-0.43
2024-12-31
→
2025-12-31
Free Cash Flow
$-10M
2025-12-31
→
2025-12-31
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
LIMNW
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
LIMNW
Peer Median
ROA
-344.7%
—
ROE
109.6%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
LIMNW
Peer Median
Debt / Equity
-0.1
—
Current Ratio
0.0
—
Quick Ratio
0.0
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
LIMNW
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
LIMNW
Peer Median
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 12
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| R&D Expense | · | $3M | |
| SG&A Expense | $3M | $644.6K | |
| Operating Expenses | $3M | $3M | |
| Operating Income | $-3M | $-3M | |
| Interest Income | $76.6K | $122.5K | |
| Other Non-op | $-7M | $-216.4K | |
| Net Income | $-10M | $-4M | |
| EPS (Basic) | $-0.43 | $-0.20 | |
| EPS (Diluted) | $-0.43 | $-0.20 | |
| Shares (Basic) | 23,753,561 | 17,500,000 | |
| Shares (Diluted) | 23,753,561 | 17,500,000 | |
| EBITDA | $-3M | · |
Balance Sheet 17
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $337.7K | $56.3K | |
| Prepaid Expense | $162.9K | $155.5K | |
| Current Assets | $500.6K | $5M | |
| PP&E (Net) | $12.2K | $941 | |
| Total Assets | $512.8K | $5M | |
| Accounts Payable | $582.2K | $1M | |
| Accrued Liabilities | · | $805 | |
| Short-term Debt | $1M | $20M | |
| Current Liabilities | $10M | $25M | |
| Total Liabilities | $10M | $25M | |
| Total Debt | $1M | · | |
| Common Stock | $2.7K | $1.8K | |
| Paid-in Capital | $29M | $9M | |
| Retained Earnings | $-39M | $-29M | |
| Stockholders' Equity | $-10M | $-19M | |
| Liabilities + Equity | $512.8K | $5M | |
| Shares Outstanding | 27,064,633 | 17,500,000 |
Cash Flow 7
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Operating Cash Flow | $-10M | $-1M | |
| CapEx | $13.1K | · | |
| Investing Cash Flow | $-788.1K | $-3M | |
| Financing Cash Flow | $11M | $4M | |
| Net Change in Cash | $281.3K | $-378.1K | |
| Taxes Paid | $0 | $0 | |
| Free Cash Flow | $-10M | · |
Profitability 2
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| ROA | -344.7% | · | |
| ROE | 109.6% | · |
Liquidity & Solvency 3
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 0.0 | · | |
| Quick Ratio | 0.0 | · | |
| Debt / Equity | -0.1 | · |
Valuation (TTM) 1
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Net Income TTM | $-10M | · |
Income Statement 12
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $600.0K | · | · | · | · | $0 | |
| SG&A Expense | $778.9K | $884.2K | $701.2K | $1M | · | $167.1K | |
| Operating Expenses | $1M | $884.2K | $701.2K | $1M | · | $167.1K | |
| Operating Income | $-1M | $-1M | $-701.2K | $-1M | $-255 | $-2M | |
| Interest Income | · | $0 | $0 | $24.4K | · | $43.5K | |
| Other Non-op | $-28.4K | $-7M | $-1M | $1M | · | $-62.7K | |
| Net Income | $-1M | $-8M | $-2M | $113.3K | $-327.5K | $-229.8K | |
| EPS (Basic) | $-0.03 | $2.19 | $-0.07 | $0.00 | $-2.55 | $2.35 | |
| EPS (Diluted) | $-0.03 | $2.19 | $-0.07 | $0.00 | $-2.55 | $2.35 | |
| Shares (Basic) | 48,398,314 | -26,555,285 | 27,007,568 | 23,301,178 | 100 | -17,500,100 | |
| Shares (Diluted) | 48,398,314 | -26,555,285 | 27,007,568 | 23,301,178 | 100 | -17,500,100 | |
| EBITDA | $-1M | · | $-701.2K | $-1M | $-255 | · |
Balance Sheet 17
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3M | $337.7K | $724.5K | $1M | · | $56.3K | |
| Prepaid Expense | $375.4K | $162.9K | $478.9K | $444.1K | · | $155.5K | |
| Current Assets | $3M | $500.6K | $1M | $2M | · | $5M | |
| PP&E (Net) | $11.2K | $12.2K | $12.8K | $198 | · | $941 | |
| Total Assets | $3M | $512.8K | $1M | $2M | · | $5M | |
| Accounts Payable | $655.1K | $582.2K | $559.2K | $431.9K | · | $1M | |
| Accrued Liabilities | · | · | · | · | $1.1K | · | |
| Short-term Debt | $1M | $1M | $1M | $1M | · | $20M | |
| Current Liabilities | $3M | $10M | $3M | $11M | · | $25M | |
| Total Liabilities | $3M | $10M | $3M | $11M | $1.1K | $25M | |
| Total Debt | $1M | · | $1M | $1M | · | · | |
| Common Stock | $5.6K | $2.7K | $2.7K | $2.6K | $0 | $1.8K | |
| Paid-in Capital | $42M | $29M | $29M | $20M | $10 | $9M | |
| Retained Earnings | $-41M | $-39M | $-31M | $-29M | $-1.1K | $-29M | |
| Stockholders' Equity | $300.6K | $-10M | $-2M | $-9M | $-1.1K | $-19M | |
| Liabilities + Equity | $3M | $512.8K | $1M | $2M | · | $5M | |
| Shares Outstanding | 55,971,633 | 27,064,633 | 27,064,633 | 26,014,633 | · | 17,500,000 |
Cash Flow 5
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-970.0K | $-386.8K | $-600.6K | $-9M | $0 | $-140.7K | |
| CapEx | · | $0 | · | · | · | · | |
| Investing Cash Flow | · | $0 | $-13.1K | $-200.0K | · | $-550.0K | |
| Financing Cash Flow | $2M | $0 | $0 | $10M | · | $700.0K | |
| Net Change in Cash | $1M | $-386.8K | $-613.7K | $1M | $0 | $9.3K |
Profitability 2
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| ROA | -53.0% | · | -271.6% | 11.9% | · | · | |
| ROE | 33.1% | · | 221.6% | -2.6% | 48.1% | · |
Liquidity & Solvency 3
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | · | 0.4 | 0.2 | · | · | |
| Quick Ratio | 1.0 | · | 0.3 | 0.1 | · | · | |
| Debt / Equity | 4.8 | · | -0.9 | -0.2 | · | · |
Valuation (TTM) 8
| Metric | Trend | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-4M | · | $-3M | $-2M | $-4M | · | |
| Market Cap | $3M | · | · | · | · | · | |
| Enterprise Value | $2M | · | · | · | · | · | |
| P/E | -0.5 | · | · | · | · | · | |
| P/B | 11.2 | · | · | · | · | · | |
| P / Tangible Book | 11.2 | · | · | · | · | · | |
| EV / EBITDA | -1.3 | · | · | · | · | · | |
| Earnings Yield | -216.7% | · | · | · | · | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Net Income | $-10M | $-4M |
| Diluted EPS | $-0.43 | $-0.20 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Debt / Equity | -0.1 | — |
| Current Ratio | 0.0 | — |
| Quick Ratio | 0.0 | — |
Cash Flow
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Free Cash Flow | $-10M | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 25 filers · $289K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 2 (+1 vs prior Q) | 1 (-3 vs prior Q) | 0 (-1 vs prior Q) | 3 (+1 vs prior Q) | -15K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| CLEAR STREET LLC | $193,234 | 805,477 | 66.88% | Shares |
| ARISTEIA CAPITAL, L.L.C. | $16,279 | 319,510 | 5.63% | Shares |
| Linden Advisors LP | $13,678 | 268,199 | 4.73% | Shares |
| Saba Capital Management, L.P. | $11,910 | 233,761 | 4.12% | Shares |
| MOORE CAPITAL MANAGEMENT, LP | $9,375 | 125,000 | 3.24% | Shares |
| MMCAP International Inc. SPC | $8,381 | 111,745 | 2.90% | Shares |
| Polar Asset Management Partners Inc. | $6,257 | 122,688 | 2.17% | Shares |
| MILLENNIUM MANAGEMENT LLC | $5,296 | 70,616 | 1.83% | Call option |
| D. E. Shaw & Co., Inc. | $2,934 | 83,353 | 1.02% | Shares |
| TORONTO DOMINION BANK | $2,633 | 35,100 | 0.91% | Shares |
| Cubist Systematic Strategies, LLC | $2,334 | 15,778 | 0.81% | Shares |
| LMR Partners LLP | $2,247 | 29,961 | 0.78% | Shares |
| Arena Capital Advisors, LLC- CA | $2,187 | 29,166 | 0.76% | Shares |
| Blue Owl Capital Holdings LP | $2,000 | 50,000 | 0.69% | Shares |
| Periscope Capital Inc. | $1,980 | 30,000 | 0.69% | Shares |
| JANE STREET GROUP, LLC | $1,821 | 24,274 | 0.63% | Shares |
| Limestone Investment Advisors LP | $1,692 | 22,562 | 0.59% | Shares |
| GTS SECURITIES LLC | $1,570 | 20,929 | 0.54% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,317 | 17,562 | 0.46% | Shares |
| WOLVERINE ASSET MANAGEMENT LLC | $1,048 | 13,976 | 0.36% | Shares |
| UBS Group AG | $338 | 4,507 | 0.12% | Shares |
| DUPONT CAPITAL MANAGEMENT CORP | $318 | 6,250 | 0.11% | Shares |
| HGC Investment Management Inc. | $94 | 1,250 | 0.03% | Shares |
| FLOW TRADERS U.S. LLC | $1 | 13,110 | 0.00% | Shares |
| Virtu Financial LLC | $1 | 10,805 | 0.00% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Valetudo Therapeutics LLC, Chris Kim | July 14, 2026 | 14.30% | Amendment | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.